This is no longer the case with both pharma and generics entering a single healthcare space and competition between generics companies increasing as each vies for share in new and international markets.
Branded generics, super generics and biobetters, each seeks to create and exploit value while affording better protection to the developer. Repositioning goes a step further by creating a stronger product through the addition of a new indication.
How we can help
Biovista B2B Services can help you:
- Find a new indication for a generic drug you are developing
- Develop novel administration routes and dosing regimes to better protect the repositioned drug
- Find a combination of any two generic drugs to treat a disease of interest or multiple diseases
- Combine an existing drug targeted at a disease with another, to provide differentiation from the competition in that disease